{
    "root": "a90640e9-c085-4602-9304-f83acda191e9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PYZCHIVA",
    "value": "20250421",
    "ingredients": [
        {
            "name": "USTEKINUMAB",
            "code": "FU77B4U5Z0"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        }
    ],
    "indications": "PYZCHIVA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA). ( 1.2 ) moderately to severely active Crohn's disease (CD). ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA). ( 1.2 )",
    "contraindications": "Psoriasis Adult Subcutaneous Recommended Dosage ( 2.1 ): Weight Range (kilograms) Recommended Dosage less than or equal to 100 kg 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks greater than 100 kg 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks Psoriasis Pediatric Patients (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.1 ): Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg greater than 100 kg 90 mg Psoriatic Arthritis Adult Subcutaneous Recommended Dosage ( 2.2 ): The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks. Psoriatic Arthritis Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.2 ) : Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg Crohn's Disease and Ulcerative Colitis Initial Adult Intravenous Recommended Dosage ( 2.3 ) : A single intravenous infusion using weight-based dosing: Weight Range (kilograms) Dose up to 55 kg 260 mg (2 vials) greater than 55 kg to 85 kg 390 mg (3 vials) greater than 85 kg 520 mg (4 vials) Crohn's Disease and Ulcerative Colitis Maintenance Adult Subcutaneous Recommended Dosage ( 2.3 ) : A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.",
    "warningsAndPrecautions": "PYZCHIVA (ustekinumab-ttwe) injection is a clear, colorless to light yellow, sterile and preservative-free solution. It is supplied as individually packaged, single-dose prefilled syringe or single-dose vial.\n                  \n                     For Subcutaneous Use\n                  \n                  \n                     Prefilled Syringes\n                  \n                  \n                     45 mg/0.5 mL (NDC 61314-651-01)\n                     90 mg/mL (NDC 61314-652-01)\n                  \n                  Each prefilled syringe is equipped with a 29 gauge fixed ½ inch needle, a needle safety guard, and a needle cover that is not made with natural rubber latex.\n                  \n                  \n                     Single-dose Vial\n                  \n                  •   45 mg/0.5 mL (NDC 61314-651-94)\n                  \n                  \n                     For Intravenous Infusion\n                  \n                  \n                     Single-dose Vial\n                  \n                  • 130 mg/26 mL (5 mg/mL) (NDC 61314-654-94)\n                  \n                     Storage and Stability\n                  \n                  Store PYZCHIVA vials, and prefilled syringes refrigerated between 2°C to 8°C (36°F to 46°F). Store PYZCHIVA vials upright. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.\n                  If needed, individual prefilled syringes may be stored at room temperature up to 30°C (86°F) for a maximum single period of up to 35 days in the original carton to protect from light. If not used within 35 days of room temperature storage, discard the prefilled syringe. The prefilled syringe may be returned to the refrigerator one time only for a maximum of 60 days. If not used within 60 days, discard the prefilled syringe. Record the date when the prefilled syringe is removed from and returned to the refrigerator on the carton in the space provided.\n                  Do not use PYZCHIVA after the expiration date on the carton or on the prefilled syringe.",
    "adverseReactions": "PYZCHIVA is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in PYZCHIVA [see Warnings and Precautions (5.5)]."
}